|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Tetracycline Treatment for COVID-19
| Title: | Tetracycline Treatment for COVID-19 |
| Authors: | Ohe, Masashi Browse this author | | Furuya, Ken Browse this author | | Goudarzi, Houman Browse this author →KAKEN DB |
| Keywords: | Severe acute respiratory syndrome coronavirus 2 | | COVID-19 | | tetracycline |
| Issue Date: | 5-Nov-2021 |
| Publisher: | Gazi University |
| Journal Title: | Gazi Medical Journal |
| Volume: | 32 |
| Issue: | 4A |
| Start Page: | 686 |
| End Page: | 687 |
| Publisher DOI: | 10.12996/gmj.2021.156 |
| Abstract: | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak that originated in late 2019 has become a serious global threat to human health. Presently, there are no drugs approved to combat the disease (COVID-19). Therefore, it is important to find effective drugs against COVID-19 and to conduct clinical trials of these drugs. Drug repurposing is a well-known strategy used to redeploy licensed drugs for newer indications, thereby providing the fastest possible transition from bench to bedside for meeting therapeutic needs. The anti-SARS-CoV-2 effects of tetracyclines (TCs), (e.g., doxycycline and minocycline), have recently attracted considerable attention. We believe that treatment with TC alone or in combination with other drugs is promising and may open the door for an international strategy to fight this emerging viral infection. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/83202 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
